Geerard Beets

Prof. Dr. Geerard Beets

orcid

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2010 in The Lancet Oncology
Verified
Journal Article
Closed access
MMMonique Maas
Monique Maas
PNPatty J Nelemans
Patty J Nelemans
VVVincenzo Valentini
Vincenzo Valentini
PDPrajnan Das
Prajnan Das
CRClaus Rödel
Claus Rödel
GBGeerard Beets
Geerard Beets

6 April 2020 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
MCMyriam Chalabi
Myriam Chalabi
LFLorenzo F. Fanchi
Lorenzo F. Fanchi
KDKrijn K. Dijkstra
Krijn K. Dijkstra
JBJosé G. Van Den Berg
José G. Van Den Berg
AAArend G. Aalbers
Arend G. Aalbers
JHJohn B. Haanen
John B. Haanen

1 June 2018 in The Lancet
Verified
Journal Article
Open access
MVMaxime J M van der Valk
Maxime J M van der Valk
DHDenise Hilling
Denise Hilling
EBEsther Bastiaannet
Esther Bastiaannet
EKElma Meershoek-Klein Kranenbarg
Elma Meershoek-Klein Kranenbarg
GBGeerard Beets
Geerard Beets
DZDavid D E Zimmerman
David D E Zimmerman
The strategy of watch and wait (W&W) in patients with rectal cancer who achieve a complete clinical response (cCR) after neoadjuvant therapy is new and offers an opportunity for patients to avoid major resection surgery. However, evidence is based on small-to-moderate sized series from specialist centres. The International Watch & Wait Database (IWWD) aims to describe the outcome of the W&W strategy in a large-scale registry of pooled individual patient data. We report the results of a descriptive analysis after inclusion of more than 1000 patients in the registry. Participating centres entered data in the registry through an online, highly secured, and encrypted research data server. Data included baseline characteristics, neoadjuvant therapy, imaging protocols, incidence of local regrowth and distant metastasis, and survival status. All patients with rectal cancer in whom the standard of care (total mesorectal excision surgery) was omitted after neoadjuvant therapy were eligible to be included in the IWWD. For the present analysis, we only selected patients with no signs of residual tumour at reassessment (a cCR). We analysed the proportion of patients with local regrowth, proportion of patients with distant metastases, 5-year overall survival, and 5-year disease-specific survival. Between April 14, 2015, and June 30, 2017, we identified 1009 patients who received neoadjuvant treatment and were managed by W&W in the database from 47 participating institutes (15 countries). We included 880 (87%) patients with a cCR. Median follow-up time was 3·3 years (95% CI 3·1-3·6). The 2-year cumulative incidence of local regrowth was 25·2% (95% CI 22·2-28·5%), 88% of all local regrowth was diagnosed in the first 2 years, and 97% of local regrowth was located in the bowel wall. Distant metastasis were diagnosed in 71 (8%) of 880 patients. 5-year overall survival was 85% (95% CI 80·9-87·7%), and 5-year disease-specific survival was 94% (91-96%). This dataset has the largest series of patients with rectal cancer treated with a W&W approach, consisting of approximately 50% data from previous cohort series and 50% unpublished data. Local regrowth occurs mostly in the first 2 years and in the bowel wall, emphasising the importance of endoscopic surveillance to ensure the option of deferred curative surgery. Local unsalvageable disease after W&W was rare. European Registration of Cancer Care financed by European Society of Surgical Oncology, Champalimaud Foundation Lisbon, Bas Mulder Award granted by the Alpe d'Huzes Foundation and Dutch Cancer Society, and European Research Council Advanced Grant.
1

10 December 2011 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
MMMonique Maas
Monique Maas
RBRegina G.H. Beets-Tan
Regina G.H. Beets-Tan
DLDoenja M.J. Lambregts
Doenja M.J. Lambregts
GLGuido Lammering
Guido Lammering
PNPatty J. Nelemans
Patty J. Nelemans
GBGeerard Beets
Geerard Beets
Purpose Neoadjuvant chemoradiotherapy for rectal cancer can result in complete disappearance of tumor and involved nodes. In patients without residual tumor on imaging and endoscopy (clinical complete response [cCR]) a wait-and-see-policy (omission of surgery with follow-up) might be considered instead of surgery. The purpose of this prospective cohort study was to evaluate feasibility and safety of a wait-and-see policy with strict selection criteria and follow-up. Patients and Methods Patients with a cCR after chemoradiotherapy were prospectively selected for the wait-and-see policy with magnetic resonance imaging (MRI) and endoscopy plus biopsies. Follow-up was performed 3 to 6 monthly and consisted of MRI, endoscopy, and computed tomography scans. A control group of patients with a pathologic complete response (pCR) after surgery was identified from a prospective cohort study. Functional outcome was measured with the Memorial Sloan-Kettering Cancer Center (MSKCC) bowel function questionnaire and Wexner incontinence score. Long-term outcome was estimated by using Kaplan-Meier curves. Results Twenty-one patients with cCR were included in the wait-and-see policy group. Mean follow-up was 25 ± 19 months. One patient developed a local recurrence and had surgery as salvage treatment. The other 20 patients are alive without disease. The control group consisted of 20 patients with a pCR after surgery who had a mean follow-up of 35 ± 23 months. For these patients with a pCR, cumulative probabilities of 2-year disease-free survival and overall survival were 93% and 91%, respectively. Conclusion A wait-and-see policy with strict selection criteria, up-to-date imaging techniques, and follow-up is feasible and results in promising outcome at least as good as that of patients with a pCR after surgery. The proposed selection criteria and follow-up could form the basis for future randomized studies.

1 February 2015 in Annals of Surgery
Verified
Journal Article
Closed access
KRKostan W. Reisinger
Kostan W. Reisinger
JVJeroen L. A. van Vugt
Jeroen L. A. van Vugt
JTJuul J. W. Tegels
Juul J. W. Tegels
CSClaire Snijders
Claire Snijders
KHKarel W. E. Hulsewé
Karel W. E. Hulsewé
MPMartijn Poeze
Martijn Poeze
To determine the association of sarcopenia with postoperative morbidity and mortality after colorectal surgery. Functional compromise in elderly colorectal surgical patients is considered as a significant factor of impaired postoperative recovery. Therefore, the predictive value of preoperative functional compromise assessment was investigated. Sarcopenia is a hallmark of functional compromise. A total of 310 consecutive patients who underwent oncologic colorectal surgery were included in a prospective digital database. Sarcopenia was assessed using the L3 muscle index utilizing Osirix on preoperative computed tomography. Groningen Frailty Indicator and Short Nutritional Assessment Questionnaire scores were used to assess frailty and nutritional compromise. Predictors for anastomotic leakage, sepsis, and mortality were analyzed by logistic regression analysis. Age was an independent predictor of mortality [P = 0.04; odds ratio, 1.17; 95% confidence interval (CI), 1.01-1.37]. Thirty-day/in-hospital mortality rate in sarcopenic patients was 8.8% versus 0.7% in nonsarcopenic patients (P = 0.001; odds ratio, 15.5; 95% CI, 2.00-120). Sarcopenia was not predictive for anastomotic leakage or sepsis. Combination of high Short Nutritional Assessment Questionnaire score, high Groningen Frailty Indicator score, and sarcopenia strongly predicted sepsis (P = 0.001; odds ratio, 25.1; 95% CI, 5.11-123), sensitivity, 46%; specificity, 97%; positive likelihood ratio, 13 (95% CI, 4.4-38); negative likelihood ratio, 0.57 (95% CI, 0.33-0.97). Functional compromise in colorectal cancer surgery is associated with adverse postoperative outcome. Assessment of functional compromise by means of a nutritional questionnaire (Short Nutritional Assessment Questionnaire), a frailty questionnaire (Groningen Frailty Indicator), and sarcopenia measurement (L3 muscle index) can accurately predict postoperative sepsis.

1 October 2004 in European Journal of Radiology
Verified
Journal Article
Closed access
JKJoo Hee Kim
Joo Hee Kim
GBGeerard Beets
Geerard Beets
MKMyeong-Jin Kim
Myeong-Jin Kim
AKAlfons G.H. Kessels
Alfons G.H. Kessels
RBRegina G.H. Beets-Tan
Regina G.H. Beets-Tan